Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis

Meaghan S. Dendy; Johannes M. Ludwig; Hyun S. Kim

doi:10.18632/oncotarget.16007

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis

Meaghan S. Dendy, Johannes M. Ludwig and Hyun S. Kim _

PDF | HTML | How to cite

Oncotarget. 2017; 8:37912-37922. https://doi.org/10.18632/oncotarget.16007

Metrics: PDF 3091 views | HTML 3424 views | ?

Abstract

Meaghan S. Dendy1,2, Johannes M. Ludwig2 and Hyun S. Kim2,3

1 Drexel University College of Medicine, Philadelphia, PA, USA

2 Department of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, New Haven, CT, USA

3 Yale Cancer Center, Yale University, New Haven, CT, USA

Correspondence to:

Hyun S. Kim, email:

Keywords: colorectal cancer, liver cancer, radioembolization, Y⁹⁰, biomarkers

Received: December 28, 2016 Accepted: February 27, 2017 Published: March 08, 2017

Abstract

This critical review aims to explore predictive and prognostic biomarkers of Yttrium-90 (Y90) radioembolization therapy of colorectal liver metastases. A brief overview of established predictive and prognostic molecular and genetic biomarkers in colorectal cancer therapies will be discussed. A review of the literature on imaging modalities, genetic, metabolic and other molecular markers and the subsequent outcomes in post-Y90 treatment will be presented. How these biomarkers and future biomarker research can inform locoregional treatment decisions in the clinical setting of metastatic colorectal cancer lesions of the liver will be explored. There are opportunities for personalized cancer treatment in the setting of Y90 radioembolization. The ability to predict tumor response after Ytrium-90 radioembolization therapy can greatly impact clinical decision making and enhance treatment outcomes, therefore further research into the field is needed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16007

Publication Alerts

Reviews:

Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis

Abstract